

Remarks

Claims 1-15 are pending in the subject application. By this Amendment, Applicants have canceled claims 3, 10, and 12-15, amended claims 1, 4, 5, 8, and 11, and added new claims 16-23. Support for the new claims can be found, for example, at page 4, lines 30-31, page 5, lines 19-27, and page 11, lines 10-13, of the subject specification. Entry and consideration of the amendments and new claims presented herein is respectfully requested. Accordingly, claims 1, 2, 4-9, 11, and 16-23 are currently before the Examiner. Favorable consideration of the pending claims is respectfully requested.

The submission of new pages 14-17 is being made to correct inadvertent typographical errors in the References section of the subject application. Entry of the new pages 14-17 in the specification is respectfully requested. Claim 8 has also been amended to correct a typographical error.

As an initial matter, Applicants gratefully acknowledge the Examiner's indication that claims 3, 4, 10, and 11 are objected to but would be allowable if rewritten into independent form to include the limitations of any base and intervening claims.

Claims 1, 2, and 5-9 are rejected under 35 USC §103(a) as obvious over Schinazi *et al.* (WO 96/22778), Hart *et al.* (1995), and Budt *et al.* (1995) in view of Torres *et al.* (1997) and Johnson *et al.* (1994). In addition, claims 12-15 are rejected under 35 USC §103(a) as obvious over Torres *et al.* (1997) in view of Budt *et al.* (1995). The Examiner asserts that the Schinazi *et al.* reference discloses methods for treating FIV using nucleoside analogues, the Hart *et al.* reference teaches methods for treating FIV infected cats by oral administration of AZT, and that the Budt *et al.* reference discloses that the compound HBY-793 is a known HIV protease inhibitor. The Examiner cites the Torres *et al.* reference as disclosing the combined use of AZT, another nucleoside analog (3TC), and a protease inhibitor for treating HIV infection in humans. The Johnson *et al.* reference is cited as teaching that FIV closely resembles HIV in genomic organization, protein composition, and morphology. The Examiner asserts that in view of the references teaching the use of combination therapy to treat HIV, and the similarity between HIV and FIV, it would have been obvious to use the claimed combination therapy to treat FIV infection. Applicants respectfully traverse.

Applicants respectfully assert that the claimed invention is not obvious over the cited references, regardless of whether the references are taken alone or in combination. In particular, Applicants respectfully assert that the use of compounds in humans to treat HIV infection does not necessarily mean that the same compounds will be successful in treating FIV infection in felines. However, in order to expedite prosecution of the subject application, Applicants have amended claim 1 and claim 5 to recite the limitation of claim 3 and claim 10, respectively. Applicants note that claims 3 and 10 were not included under either of the §103 rejections and that the Examiner indicated these claims as containing allowable subject matter. Thus, claims 1 and 5, and those claims dependent therefrom, should be allowable. In addition, Applicants have canceled claims 12-15, thereby rendering the rejection of those claims moot. Accordingly, reconsideration and withdrawal of the rejections under 35 USC §103(a) is respectfully requested.


It should be understood that the amendments presented herein have been made solely to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants' agreement with or acquiescence in the Examiner's position.

In view of the foregoing remarks and amendments to the claims, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,



Doran R. Pace  
Patent Attorney  
Registration No. 38,261  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address: 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

DRP/sl

Attachments: Marked-Up Version of Amended Claims; New pages 14-17 (References) of the subject specification; Marked-Up Version of References pages.

Marked-Up Version of Amended Claims

Claim 1 (amended):

1. A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT) and another nucleoside analog, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claim 4 (amended):

4. The method according to claim [3] 1, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

Claim 5 (amended):

5. A method for treating or preventing infection of feline immunodeficiency virus (FIV) in a feline animal, said method comprising administering to said feline animal an effective amount of azidothymidine (AZT), another nucleoside analog and an inhibitor of a retroviral protease, and wherein said feline animal receives bone marrow transplantation after total body irradiation.

Claim 8 (amended):

8. The method [accoding] according to claim 5, wherein said inhibitor of a retroviral protease is designated as HBY-793 and has the structure shown in Figure 4.

Claim 11 (amended):

11. The method according to claim [10] 5, wherein the transplanted cells are selected from the group consisting of allogeneic cells and autologous cells.

# References

- 5 Boucher, C.A.B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M.A. Wainberg, and J.M. Cameron (1993) "High-level resistance to (-) enantiomeric 2'-deoxy-3' thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase" *Antimicrob. Agents Chemother.* 37:2231-2234.
- 10 Deeks, S.G., M. Smith, M. Holodniy, J.O. Kahn (1997) "HIV-1 protease inhibitors" *J. Am. Med. Assoc.* 277:145-153.
- 15 Bb Diehi, L.J., C.K. Mathiason-Dubard, L.L. O'Neil, and E.A. Hoover (1995) "Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR" *J. Virol.* 69:2328-2332.
- 20 Dunn, B.M., A. Gustchina, A. Wlodawer, and J. Kay (1994) "Subsite preferences of retroviral proteinases" *Meth. Enzymol.* 241:254-278.
- 25 Gardner, M.B. (1991) "Mini-review. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents" *Antiviral Res.* 15:267-286.
- Green, W.K., J. Meers, G. del Fierro, P.R. Carnegie, and W.F. Robinson (1993) "Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats" *Arch. Virol.* 133:51-62.
- Harrigan, R. (1995) "Measuring viral load in the clinical setting" *J. Acquir. Immune Defic. Syndr. Hum Retrovirol.* 10(Suppl. 1):S34-S40.
- 30 Hart, S., and I. Nolte (1995) "Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT)" *J. Vet. Med. A.* 42:397-409.
- 35 Hartmann, K., A. Donath, B. Beer, H.F. Egberink, M.C. Horzinek, H. Lutz, G. Hoffmann-Fezer, I. Thum, and S. Thefeld (1992) "Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms" *Vet. Immunol. Immunopathol.* 35:167-175.
- 40 Hayes, K.A., L.J. Lafrado, J.G. Erickson, J.M. Marr, and L.E. Mathes (1993) "Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats" *J. Acquir. Immune Defic. Syndr.* 6:127-134.

- Hayes, K.A., J.G. Wilkinson, R. Frick, S. Francke, and L.E. Mathes (1995) "Early suppression of viremia by ZDV dose not alter the spread of feline immunodeficiency virus infection in cats" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 9:114-122.
- 5 Johnson, C.M., B.A. Torres, H. Koyama, and J.K. Yamamoto (1994) "FIV as a model for AIDS vaccination" *AIDS Res. Hum. Retroviruses* 10:225-228.
- Katlama, C., and the European Lamivudine HIV Working Group (1994) "Combination 3TC (lamivudine) / ZVD (zidovudine) versus ZVD monotherapy in ZVD naive HTV-1  
10 positive patients with CD4 of 100-400 cells/mm<sup>3</sup>, abstr" *AIDS* 8(Suppl. 4):56.
- Lange, J.M.A. (1995) "Triple combinations: present and future" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 10(Suppl. 1):S77-S82.
- 15 Larder, B.A. (1995) "Viral resistance and the selection of antiretroviral combinations" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 10(Suppl. 1):S28-S33.
- Magnani, M., L. Rossi, A. Fraternali, L. Silvotti, F. Quintavalla, G. Piedimonte, D. Matteucci, F. Baldinotti, and M. Bendinelli (1994) "Feline immunodeficiency virus  
20 infection of macrophages: In vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes" *AIDS Res. Hum. Retroviruses* 10:1179-1186.
- Meers, J., G.M. del Fierro, R. B. Cope, H. S. Park, W. K. Greene, and W. F. Robinson (1993) "Feline immunodeficiency virus infection: plasma, but not peripheral blood  
25 mononuclear cell virus titer is influenced by zidovudine and cyclosporine" *Arch. Virol.* 132:67-81.
- Mishell, B.B., S.M. Shilgi, C. Henry, E.L. Chan, I. North, R. Gallily, M. Slomich, K. Miller, I. Marbrook, D. Parks, and A.H. Good (1980) "Preparation of mouse cell  
30 suspensions" p.3-27. In B.B. Mishell and S.M. Shiigi (ed.), *Selected methods in cellular immunology*. W.H. Freeman and Co. San Francisco, CA.
- Newell, M.L., and D.M. Gibb (1995) "A risk-benefit assessment of zidovudine in the prevention of perinatal HIV transmission" *Drug-Saf.* 12:274-281.
- 35 North, T.W., G.L.T. North, and N.C. Pedersen (1989) "Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immunodeficiency syndrome" *Antimicrob. Agents Chemother.* 33:915-919.
- 40 Okada, S., R. Pu, E. Young, W. Stoffs, and J.K. Yamamoto (1994) "Superinfection of cats with FIV subtypes A and B" *AIDS Res. Hum. Retroviruses* 10:1739-1746.

- Paul, D.B., M.C. Kuhns, A. L. McNamara, J.C. Jr. Pottage, and G.T. Spear (1995) "Short-term stability of HIV provirus levels in the peripheral blood of HIV-infected individuals" *J. Med. Virol.* 47:292-297.
- 5 Pedersen, N.C., E.W. Ho, M.L. Brown, and J.K. Yamamoto (1987) "Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome" *Science* 235:790-793.
- 10 Philpott, M.S., J.P. Ebner, and E.A. Hoover (1992) "Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction" *Vet. Immunol Immunopathol.* 35:155-166.
- 15 Rey, M.A, B. Spire, D. Dormont, F. Barre-Sinoussi, L. Montagnier, and J.C. Chermann (1984) "Characterization of the RNA dependant DNA polymerase of new human T-lymphotropic retrovirus (lymphadenopathy associated virus)" *Biochem. Biophys. Res. Commun.* 21:1247-1253.
- 20 Siebelink, K.H.J., I-H. Chu, G.F. Rimmelzwaan, K. Weijer, R.V. Herwijnen, P. Knell, H.F. Egberink, M.L. Bosch, and A.D.M.E. Osterhaus (1990) "Feline immunodeficiency virus (FIV) infection in the cats as a model for HIV infection in man: FIV-induced impairment of immune function" *AIDS Res. Hum. Retroviruses* 6:1373-1378.
- 25 Smyth, N.R., M. Bennett, R.M. Gaskell, C.M. McCracken, C.A. Hart, and J.L. Howe (1994) "Effect of 3'azido-2'3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats" *Res. Vet. Sci.* 57:220-224.
- Staszewski, S. (1995) "Zidovudine and lamivudine: results of phase III studies" *J. Acquir. Immune Defic. Syndr. Hum Retrovirol.* 10(Suppl. 1):557.
- 30 Tellier, M.C., J.M. Soos, R. Pu, and J.K. Yamamoto (1997) "Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunization with FIV vaccines" *Vet. Microbiol.* 57:1-11.
- 35 Tisdale, M., S.D. Kemp, N.R. Parry, and B.A. Larder (1993) "Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3 -thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase" *Proc Natl. Acad. Sci. USA* 90:5653-5656.
- 40 Torres, R.A. and M.R. Barr (1997) "Combination antiretroviral therapy for HIV infection" *Infect. Med.* 14:142-160.

B6  
Cost

Wlodawer, A., A. Gustchina, L. Reshetnikova, J. Lubkowski, A. Zdanov, K.Y. Hui, E.L. Angleton, W.G. Farmerie, M.M. Goodenow, D. Bhatt, L. Zhang, and B.M. Dunn. (1995) "Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus" *Nature Struct. Biol.* 2:480-488.

5

Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Loule, H. Zochlinski, E. Pembroke, and M.B. Gardner (1991) "Experimental vaccine protection against feline immunodeficiency virus" *AIDS Res. Hum. Retroviruses* 7:911-922.

10

Yamamoto, J.K., N.C. Pedersen, E.W. Ho, T. Okuda, and G.H. Theilen (1988) "Feline immunodeficiency syndrome - A comparison between feline T-lymphotropic lentivirus and feline leukemia virus" *Leukemia* 2(Suppl. 12):204S-215S.

15

Yamamoto J.K., E. Sparger, E.W. Ho, P.R. Andersen, T.P. O'Connor, C.P. Mandell, L. Lowenstine, R. Munn, and N.C. Pedersen (1988) "Pathogenesis of experimentally induced feline immunodeficiency virus infection in cats" *Am. J. Vet. Res.* 49:1246-1258.

---

VS  
Cont

MARKED-UP VERSION OF REFERENCESReferences

- 5 Boucher, C.A.B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M.A. Wainberg, and J.M. Cameron (1993) "High-level resistance to (-) enantiomeric 2'-deoxy-3' thiacytidine in vitro is due to one amino acid substitution in the catalytic site [in] of human immunodeficiency virus type 1 reverse transcriptase" *Antimicrob. Agents Chemother.* 37:2231-2234.
- 10 Deeks, S.G., M. Smith, M. Holodniy, J.O. Kahn (1997) "HIV-1 protease inhibitors" *J. Am. Med. Assoc.* 277:145-153.
- 15 Diehi, L.J., C.K. Mathiason-Dubard, L.L. O'Neil, and E.A. Hoover (1995) "Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR" *J. Virol.* 69:2328-2332.
- 20 Dunn, B.M., A. Gustchina, A. Wlodawer, and J. Kay (1994) "Subsite [preference] preferences of retroviral proteinases" *Meth. Enzymol.* 241:254-278.
- Gardner, M.B. (1991) "Mini-review. Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents" *Antiviral Res.* 15:267-286.
- 25 Green, W.K., J. Meers, G. del Fierro, P.R. Carnegie, and W.F. Robinson (1993) "Extensive sequence variation of feline immunodeficiency virus env genes in isolates from naturally infected cats" *Arch. Virol.* 133:51-62.
- 30 Harrigan, R. (1995) "Measuring viral load in the clinical setting" *J. Acquir. Immune Defic. Syndr. Hum Retrovirol.* [10(Suppl. 1):534-540] 10(Suppl. 1):S34-S40.
- Hart, S., and I. Nolte (1995) "Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT)" *J. Vet. Med. A.* 42:397-409.
- 35 [Hartmaun] Hartmann, K, A. Donath, B. Beer, H.F. Egberink, M.C. Horzinek, H. Lutz, G. Hoffmann-Fezer, I. Thum, and S. Thefeld (1992) "Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms" *Vet. Immunol. Immunopathol.* 35:167-175.
- 40 [Hayees] Hayes, K.A., L.J. Lafrado, J.G. Erickson, J.M. Marr, and L.E. Mathes (1993) "Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats" *J. Acquir. Immune Defic. Syndr.* 6:127-134.

- [Hayees] Hayes, K.A., J.G. [Wilkison] Wilkinson, R. Frick, S. Francke, and L.E. Mathes (1995) "Early suppression of viremia by ZDV dose not alter the spread of feline immunodeficiency virus infection in cats" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* 9:114-122.
- Johnson, [M.C.] C.M., B.A. Torres, H. Koyama, and J.K. Yamamoto (1994) "FIV as a model for AIDS vaccination" *AIDS Res. Hum. Retroviruses* 10:225-228.
- Katlama, C., and the European [Lainivudine] Lamivudine HIV Working Group (1994) "Combination 3TC (lamivudine) / ZVD (zidovudine) versus ZVD monotherapy in ZVD naive HTV-1 positive patients with CD4 of 100-40Q cells/mm3, abstr" *AIDS* 8(Suppl. 4):56.
- Lange, J.M.A. (1995) "Triple combinations: present and future" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* [10(Suppl. 1):577-582] 10(Suppl. 1):S77-S82.
- Larder, B.A. (1995) "Viral resistance and the selection of antiretroviral combinations" *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* [10(Suppl.1):528-533] 10(Suppl. 1):S28-S33.
- Magnani, M., L. Rossi, A. Fraternale, L. Silvotti, F. Quintavalla, G. Piedimonte, D. Matteucci, F. Baldinotti, and M. Bendinelli (1994) "Feline immunodeficiency virus infection of macrophages: In vitro and in vivo inhibition by dideoxycytidine-5'-triphosphate-loaded erythrocytes" *AIDS Res. Hum. Retroviruses* 10:1179-1186.
- Meers, J., G.M. del Fierro, [IL] R. B. Cope, H. S. Park, W. K Greene, and W. F. Robinson (1993) "Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine" *Arch. Virol.* 132:67-81.
- Mishell, B.B., S.M. Shilgi, C. Henry, E.L. Chan, I. North, R. Gallily, M. Slomich, K Miller, I. Marbrook, D. Parks, and A.H. Good (1980) "Preparation of mouse cell suspensions" p.3-27. In B.B. Mishell and S.M. Shiigi (ed.), *Selected methods in cellular immunology*. W.H. Freeman and Co. San Francisco, CA.
- Newell, M.L., and D.M. Gibb (1995) "A risk-benefit assessment of zidovudine in the prevention of perinatal HIV trarisnuSSION" *Drug-Saf.* [12:274-282] 12:274-281.
- North, T.W., G.L.T. North, and N.C. Pedersen (1989) "Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immunodeficiency syndrome" *Antimicrob. Agents Chemother.* 33:915-919.

- Okada, S., R. Pu, E. Young, W. Stoffs, and J.K. Yamamoto (1994) "Superinfection of cats with FIV subtypes A and B" *AIDS Res. Hum. Retroviruses* 10:1739-1746.
- 5 Paul, D.B., M.C. Kuhns, A. [Al.] L. McNamara, J.C. Jr. Pottage, and G.T. Spear (1995) "Short-term stability of HIV provirus levels in the peripheral blood of HIV-infected individuals" *J. Med. Virol.* 47:292-297.
- 10 Pedersen, N.C., E.W. Ho, M.L. Brown, and J.K. Yamamoto (1987) "Isolation of a [lymphotropic] T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome" *Science* 235:790-793.
- 15 Philpott, M.S., J.P. Ebner, and E.A. Hoover (1992) "Evaluation of 9-(2-phosphonylmethoxyethyl) adenine therapy for feline immunodeficiency virus using a quantitative polymerase chain reaction" *Vet. [Immunol] Immunol Immunopathol.* 35:155-166.
- 20 Rey, M.A., B. Spire, D. Dormont, F. Barre-Sinoussi, L. Montagnier, and J.C. Chermann (1984) "Characterization of the RNA dependant DNA polymerase of new human T-lymphotropic retrovirus (lymphadenopathy associated virus)" *Biochem. Biophys. Res. Commun.* 21:1247-1253.
- 25 Siebelink, K.H.J., I-H. Chu, G.F. Rimmelzwaan, K. Weijer, R.V. Herwijnen, P. [Kenell] Knell, H.F. [Egberink] Egberink, M.L. Bosch, and [A.E.M.E.] A.D.M.E. Osterhaus (1990) "Feline immunodeficiency virus (FIV) infection in the cats as a model for HIV infection in man: FIV-induced impairment of immune [ftmction] function" *AIDS Res. Hum. Retroviruses* 6:1373-1378.
- 30 [Smith] Smyth, N.R., M. Bennett, R.M. Gaskell, C.M. McCracken, C.A. Hart, and J.L. Howe (1994) "Effect of 3'azido-2'3'-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats" *Res. Vet. Sci.* 57:220-224.
- 35 Staszewski, S. (1995) "Zidovudine and lamivudine: results of phase III studies" *J. Acquir. Immune Defic. Syndr. Hum Retrovirol.* 10(Suppl. 1):557.
- Tellier, M.C., J.M. Soos, R. Pu, and J.K. Yamamoto (1997) "Development of FIV-specific cytolytic T-lymphocyte responses in cats upon immunization with FIV vaccines" *Vet. Microbiol.* 57:1-11.
- 40 Tisdale, M., S.D. Kemp, N.R. Parry, and B.A. Larder (1993) "Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3 -thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase" *Proc Natl. Acad. Sci. USA* [90:5663-5666] 90:5653-5656.

Torres, R.A. and M.R. Barr (1997) "Combination antiretroviral therapy for HIV infection"  
*Infect. Med.* 14:142-160.

5 Wlodawer, A., A. Gustchina, L. Reshetnikova, J. Lubkowski, A. Zdanov, K.Y. Hui, E.L.  
Angleton, W.G. Farmerie, M.M. Goodenow, D. Bhatt, L. Zhang, and B.M. Dunn.  
(1995) "Structure of an inhibitor complex of the [protease] proteinase from feline  
immunodeficiency virus" *Nature Struct. Biol.* 2:480-488.

10 Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Loule, H. Zochlinski, E. Pembroke, and M.B.  
Gardner (1991) "Experimental vaccine protection against feline immunodeficiency  
virus" *AIDS Res. Hum. Retroviruses* 7:911-922.

15 Yamamoto, J.K., N.C. Pedersen, E.W. Ho, T. Okuda, and G.H. Theilen (1988) "Feline  
immunodeficiency syndrome - A comparison between feline T-lymphotropic  
lentivirus and feline leukemia virus" *Leukemia* [2(Suppl. 12):2045-2155] 2(Suppl.  
12):204S-215S.

20 Yamamoto J.K., E. Sparger, E.W. Ho, P.R. Andersen, T.P. O'Connor, C.P. Mandell, L.  
Lowenstine, R. Munn, and N.C. Pedersen (1988) "Pathogenesis of experimentally  
induced feline immunodeficiency virus infection in cats" *Am. J. Vet. Res.* 49:1246-  
1258.